Compare AGNC Investment Corp (AGNC) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGNC Investment Corp vs Alnylam Pharmaceuticals, Inc. — how do they compare? AGNC Investment Corp trades at $10.96 (market cap $12.76B), while Alnylam Pharmaceuticals, Inc. trades at $322.01 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× AGNC Investment Corp's market cap, and AGNC Investment Corp pays a 12.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AGNC | ALNY | |
|---|---|---|
Market Cap | $12.76B | $42.94B |
Sector | Financials | Health |
52-Week High | $12.17 | $491.22 |
52-Week Low | $9.20 | $278.09 |
Dividend Yield | 12.95% | — |
Enterprise Value | — | $41.20B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
